Basic clinicobiological features of the ARC, ADM, and CLL4 trials
| Variable . | ADM . | ARC . | CLL4 . |
|---|---|---|---|
| Patients, n | 122 | 124 | 359 |
| Age at randomization, median (range), y | 62 (39-77) | 61 (36-80) | 64 (41-86) |
| Sex, n (%) | |||
| Male | 97 (80) | 90 (73) | 270 (75) |
| Female | 25 (20) | 34 (27) | 89 (25) |
| Binet stage, n (%) | |||
| A | 15 (12) | 23 (18.5) | 93 (26) |
| B | 61 (50) | 62 (50.5) | 155 (43) |
| C | 46 (38) | 39 (31) | 111 (31) |
| IGHV mutational status, n (%) | |||
| IGHV-U | 60 (52) | 65 (60) | 180 (61) |
| IGHV-M | 56 (48) | 43 (40) | 117 (39) |
| del(11q), n (%) | |||
| Absent | 98 (81) | 98 (82) | 256 (78) |
| Present | 23 (19) | 22 (18) | 72 (22) |
| del(17p), n (%) | |||
| Absent | 111 (92) | 111 (95) | 300 (93) |
| Present | 10 (8) | 6 (5) | 23 (7) |
| Epigenetic subgroup, n (%) | |||
| n-CLL | 52 (43) | 60 (49) | 186 (52) |
| i-CLL | 36 (29) | 34 (27) | 125 (35) |
| m-CLL | 34 (29) | 30 (24) | 48 (13) |
| Variable . | ADM . | ARC . | CLL4 . |
|---|---|---|---|
| Patients, n | 122 | 124 | 359 |
| Age at randomization, median (range), y | 62 (39-77) | 61 (36-80) | 64 (41-86) |
| Sex, n (%) | |||
| Male | 97 (80) | 90 (73) | 270 (75) |
| Female | 25 (20) | 34 (27) | 89 (25) |
| Binet stage, n (%) | |||
| A | 15 (12) | 23 (18.5) | 93 (26) |
| B | 61 (50) | 62 (50.5) | 155 (43) |
| C | 46 (38) | 39 (31) | 111 (31) |
| IGHV mutational status, n (%) | |||
| IGHV-U | 60 (52) | 65 (60) | 180 (61) |
| IGHV-M | 56 (48) | 43 (40) | 117 (39) |
| del(11q), n (%) | |||
| Absent | 98 (81) | 98 (82) | 256 (78) |
| Present | 23 (19) | 22 (18) | 72 (22) |
| del(17p), n (%) | |||
| Absent | 111 (92) | 111 (95) | 300 (93) |
| Present | 10 (8) | 6 (5) | 23 (7) |
| Epigenetic subgroup, n (%) | |||
| n-CLL | 52 (43) | 60 (49) | 186 (52) |
| i-CLL | 36 (29) | 34 (27) | 125 (35) |
| m-CLL | 34 (29) | 30 (24) | 48 (13) |